Myelodysplastic Syndrome Related to Successful Treatment With 177 Lu-PSMA for Metastatic Castration-Refractory Prostate Cancer.
| Autor: | Vija Racaru L, Krim M; From the Department of Nuclear Medicine, Oncopole Claudius Regaud., Rivet V; Department of Internal Medicine and Immunopathology, Oncopole Claudius Regaud, Toulouse, France., Mourey L; From the Department of Nuclear Medicine, Oncopole Claudius Regaud., Courbon PF |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical nuclear medicine [Clin Nucl Med] 2024 Oct 01; Vol. 49 (10), pp. 975-977. Date of Electronic Publication: 2024 May 20. |
| DOI: | 10.1097/RLU.0000000000005251 |
| Abstrakt: | Abstract: 177 Lu-vipivotide tetraxetan ( 177 Lu-PSMA-617/LuPSMA) received recent EMA approval for metastatic castration-resistant prostate cancer, with promising data for earlier stages. Secondary myeloid neoplasm following exposure to DNA-damaging therapy (therapy-related myelodysplastic syndrome [MDS]) is a rare severe complication of 177 Lu-oxodotreotide. We present a 77-year-old man, with synchronous liver, bone, and lymph node metastatic prostate cancer, having developed a low-risk MDS with SF3B1 mutation, 1 month after the sixth administration of LuPSMA. Although on partial metabolic and biological response with PSA nadir at 7 months after therapy, life quality was significantly altered by MDS. Competing Interests: Conflicts of interest and sources of funding: none declared. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|